MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Journal of drugs in dermatology : JDD · 2011

Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.

Gottlieb Alice B, Gordon Kenneth, Giannini Edward H, Mease Philip, Li Juan, Chon Yun, Maddox Judy, Weng Haoling H, Wajdula Joseph, Lin Shao-Lee, Baumgartner Scott W

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Assessment of associations between etanercept treatment and rare adverse events has been limited by the size of clinical trial populations. The authors examined the collective safety of etanercept in clinical trials across approved indications.

PATIENTS AND

METHODS

Forty-nine U.S. and non-U.S. trials of etanercept, involving up to 13,977 patients for approved indications, with final trial reports as of May 2006, were selected from the Amgen Inc. clinical trials database. Exposure-adjusted rates of serious infections, opportunistic infections, malignancies, and deaths were reported by trial, indication, and dosage.

RESULTS

Rates of serious infections were generally similar between etanercept and controls. Overall rates of opportunistic infections and tuberculosis were low. The standardized incidence ratio (SIR) (95% CI) for malignancy was 1.00 (0.83-1.19) for all etanercept patients across all indications. The SIR for lymphoma for patients with rheumatoid arthritis was 3.45 (1.83-5.89); all other indications reported SIRs similar to those observed in the general population. The SIRs for cutaneous squamous cell carcinoma in patients with psoriasis relative to the general population with high or low sun exposure were 2.09 (1.27-3.22) and 4.96 (3.03-7.66), respectively. SIRs were less than 1.0 for all other indications regardless of sun exposure. Rates of melanoma and basal cell carcinoma were not significantly different from those in the general population. There was no increase in mortality associated with etanercept use relative to control populations.

CONCLUSION

These data support the overall tolerability of etanercept across approved indications.

Для цитирования: Gottlieb Alice B, Gordon Kenneth, Giannini Edward H, Mease Philip, Li Juan, Chon Yun, Maddox Judy, Weng Haoling H, Wajdula Joseph, Lin Shao-Lee, Baumgartner Scott W. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.. Journal of drugs in dermatology : JDD. 2011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.